Thema: US9186403013
VCNX, US9186403013
bull-and-bear-7965522_1920.jpg - Foto: THN
Vaccinex stock: Melanoma study supports pepinemab immune strategy
Vaccinex stock is tied to new pepinemab findings in melanoma. The pilot found immune remodeling, not proven clinical benefit.
ad-hoc-news.de, heute 00:59 Uhr
VCNX, US9186403013
Vaccinex stock: Vaccinex reports 38-patient melanoma findings. ...
Revenue reached USD 2.10 million in fiscal year 2025. The next report date listed for Vaccinex stock is November 16, 2026.
ad-hoc-news.de, 24.10.26 00:14 Uhr
VCNX, US9186403013
Vaccinex publishes melanoma findings: what they mean for ...
Vaccinex reported findings from a 38-patient melanoma study on October 7, 2026. For Vaccinex stock, the study was not powered to prove efficacy.
ad-hoc-news.de, 16.10.26 01:11 Uhr
VCNX, US9186403013
Vaccinex stock fell 1.94 percent to USD 1.01 at OTC Markets ...
